LLY: Retatrutide’s Head-to-Head Win and Sleep Apnea Franchise Expand the Lead
Eli Lilly continues to widen its advantage in the cardiometabolic market. Yesterday’s topline results from the Phase 3 TRANSCEND-T2D-2 trial showed retatrutide (the company’s triple GIP/GLP-1/glucagon agonist) superior to the highest approved dose of Ozempic (semaglutide 2 mg) in adults with type 2 diabetes. At 80 weeks, both the 9 mg and 12 mg doses of retatrutide reduced A1C by an average of 2.2 percentage points versus 1.8 points for Ozempic. Weight loss was more than double: 19.5% (44.3 lbs) and 20.9% (47.4 lbs) versus 9.4% (20.9 lbs). Retatrutide also produced greater improvements in non-HDL cholesterol, triglycerides, and systolic blood pressure. These results mark the sixth successful Phase 3 readout for the molecule and reinforce its differentiation versus single-agonist GLP-1s. In obesity trials such as TRIUMPH-1, the 12 mg dose has previously delivered roughly 25–28% mean weight loss at 80 weeks (depending on estimand), levels approaching bariatric surgery. Lilly expects to file for approval in early 2027.
Separately, the sleep apnea indication is already a commercial reality with tirzepatide (Zepbound). In December 2024 the FDA approved Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-OSA trials, patients lost ~18–20% of body weight and experienced 25–29 fewer apnea-hypopnea events per hour versus ~5–6 on placebo. Up to half of treated patients achieved remission or mild, non-symptomatic disease after one year. Retatrutide has shown similarly large AHI reductions in its Phase 3 program, suggesting the franchise can expand further as more potent agents arrive. Together these data support durable growth in Mounjaro/Zepbound while positioning retatrutide as the next step-change asset.
Key risks include higher gastrointestinal side-effect rates and treatment discontinuations observed with retatrutide versus Ozempic in the head-to-head study, which could limit real-world uptake at the highest doses. Pricing and reimbursement pressure remain intense given the size of the obesity and diabetes markets, and competition is intensifying from Novo Nordisk’s pipeline (including CagriSema) as well as oral and multi-agonist entrants. Manufacturing scale-up, potential cannibalization of existing tirzepatide sales, and the usual long-term safety and cardiovascular-outcome uncertainties for a new triple agonist also warrant monitoring. The valuation already embeds substantial success; any delay in the retatrutide filing or softer commercial execution would compress the multiple.